Affiliation:
1. From the Laboratoire Central d'Hématologie et INSERM U462; Service d'Hématologie Pédiatrique; Unité de Thérapie Cellulaire; Service de Greffe de Moelle osseuse; Laboratoire de Thérapie Génique Hématologique; Laboratoire d'Immunogénétique Humaine; Institut Universitaire d'Hématologie (IUH); Hopital Saint-Louis, Paris, France; Department of Pediatric Oncology, Dana Farber Cancer Institute, Children's Hospital Boston; and Harvard Medical School, Boston, MA.
Abstract
AbstractFanconi anemia (FA) is characterized by congenital abnormalities, bone marrow failure, chromosome fragility, and cancer susceptibility. Eight FA-associated genes have been identified so far, the products of which function in the FA/BRCA pathway. A key event in the pathway is the monoubiquitination of the FANCD2 protein, which depends on a multiprotein FA core complex. In a number of patients, spontaneous genetic reversion can correct FA mutations, leading to somatic mosaicism. We analyzed the FA/BRCA pathway in 53 FA patients by FANCD2 immunoblots and chromosome breakage tests. Strikingly, FANCD2 monoubiquitination was detected in peripheral blood lymphocytes (PBLs) in 8 (15%) patients. FA reversion was further shown in these patients by comparison of primary fibro-blasts and PBLs. Reversion was associated with higher blood counts and clinical stability or improvement. Once constitutional FANCD2 patterns were determined, patients could be classified based on the level of FA/BRCA pathway disruption, as “FA core” (upstream inactivation; n = 47, 89%), FA-D2 (n = 4, 8%), and an unidentified downstream group (n = 2, 4%). FA-D2 and unidentified group patients were therefore relatively common, and they had more severe congenital phenotypes. These results show that specific analysis of the FA/BRCA pathway, combined with clinical and chromosome breakage data, allows a comprehensive characterization of FA patients.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Reference43 articles.
1. Alter BP. Inherited bone marrow failure syndromes. In: Nathan DG, Ginsburg D, Orkin SH, Look AT, eds. Hematology of Infancy and Childhood. Vol 1. 6th ed. Philadelphia, PA: Saunders; 2003: 280-363.
2. Auerbach AD, Buchwald M, Joenje H. Fanconi anemia. In: Scriver CR, ed. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGraw-Hill; 2001: 753-768.
3. Joenje H, Patel KJ. The emerging genetic and molecular basis of Fanconi anaemia. Nat Rev Genet. 2001;2: 446-457.
4. Levitus M, Rooimans MA, Steltenpool J, et al. Heterogeneity in Fanconi anemia: evidence for two new genetic subtypes. Blood. 2003;103: 2498-2503.
5. Strathdee CA, Gavish H, Shannon WR, Buchwald M. Cloning of cDNAs for Fanconi's anaemia by functional complementation. Nature. 1992; 356: 763-767.
Cited by
114 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献